TY - JOUR
T1 - Factors affecting subjective memory complaints in the AIBL aging study
T2 - biomarkers, memory, affect, and age
AU - Buckley, R.
AU - Saling, M. M.
AU - Ames, D.
AU - Rowe, C. C.
AU - Lautenschlager, N. T.
AU - MacAulay, S. L.
AU - Martins, R. N.
AU - Masters, C. L.
AU - O'Meara, T.
AU - Savage, G.
AU - Szoeke, C.
AU - Villemagne, V. L.
AU - Ellis, K. A.
AU - The AIBL Research Group
PY - 2013/8
Y1 - 2013/8
N2 - Background: The prognostic value of subjective memory complaints (SMCs) i. The diagnosis of dementia o. The Alzheimer's type is unclear. While some studies have found an association between SMCs and cognitive decline, many have found a stronger association with depression, which raises questions about their diagnostic utility. Methods: We examine. The cross-sectional association between SMC severity (as measured usin. The MAC-Q, a brief SMC questionnaire) and affect, memory, and Alzheimer's disease (AD) biomarkers (β-amyloid deposition an. The apolipoprotein E Î4 (APOEÎ4) allele) in healthy elderly controls (HC; M = 78.74 years, SD = 6.7) and individuals with mild cognitive impairment (MCI; M = 72.74 years, SD = 8.8). We analyzed a subset of individuals drawn fro. The Australian Imaging Biomarkers and Lifestyle (AIBL) Study of Aging. Results: SMCs were more severe in MCI patients than in HCs. SMC severity was related to affective variables an. The interaction between age and group membership (HC/MCI). Withi. The HC group, SMC severity was related to affective variables only, while severity correlated only with age i. The MCI group. SMCs were not related to cognitive variables or AD biomarkers. Conclusion: SMCs were related to solely by poorer mood (greater depressive and anxious symptomatology) i. The cognitively healthy elderly however mean levels were subclinical. This finding argues fo. The assessment of affective symptomatology in conjunction with cognitive assessment in elderly memory complainers. Future AIBL research will focus on assessing other AD biomarkers, such as brain atrophy and Aβ plasma markers, in relation to complaint severity. Once our 36-month follow-up data are collected, we propose to assess whether SMCs can predict future cognitive decline.
AB - Background: The prognostic value of subjective memory complaints (SMCs) i. The diagnosis of dementia o. The Alzheimer's type is unclear. While some studies have found an association between SMCs and cognitive decline, many have found a stronger association with depression, which raises questions about their diagnostic utility. Methods: We examine. The cross-sectional association between SMC severity (as measured usin. The MAC-Q, a brief SMC questionnaire) and affect, memory, and Alzheimer's disease (AD) biomarkers (β-amyloid deposition an. The apolipoprotein E Î4 (APOEÎ4) allele) in healthy elderly controls (HC; M = 78.74 years, SD = 6.7) and individuals with mild cognitive impairment (MCI; M = 72.74 years, SD = 8.8). We analyzed a subset of individuals drawn fro. The Australian Imaging Biomarkers and Lifestyle (AIBL) Study of Aging. Results: SMCs were more severe in MCI patients than in HCs. SMC severity was related to affective variables an. The interaction between age and group membership (HC/MCI). Withi. The HC group, SMC severity was related to affective variables only, while severity correlated only with age i. The MCI group. SMCs were not related to cognitive variables or AD biomarkers. Conclusion: SMCs were related to solely by poorer mood (greater depressive and anxious symptomatology) i. The cognitively healthy elderly however mean levels were subclinical. This finding argues fo. The assessment of affective symptomatology in conjunction with cognitive assessment in elderly memory complainers. Future AIBL research will focus on assessing other AD biomarkers, such as brain atrophy and Aβ plasma markers, in relation to complaint severity. Once our 36-month follow-up data are collected, we propose to assess whether SMCs can predict future cognitive decline.
UR - http://www.scopus.com/inward/record.url?scp=84880105399&partnerID=8YFLogxK
U2 - 10.1017/S1041610213000665
DO - 10.1017/S1041610213000665
M3 - Article
VL - 25
SP - 1307
EP - 1315
JO - International Psychogeriatrics
JF - International Psychogeriatrics
SN - 1041-6102
IS - 8
ER -